NSABP FB-9: A Phase II Randomized Clinical Trial Evaluating Neoadjuvant NSABP Chemotherapy Regimens with Weekly Paclitaxel or Eribulin Followed by Doxorubicin and Cyclophosphamide in Women with Locally Advanced HER2-Negative Breast Cancer
Print this page
NSABP FB-9: A Phase II Randomized Clinical Trial Evaluating Neoadjuvant NSABP Chemotherapy Regimens with Weekly Paclitaxel or Eribulin Followed by Doxorubicin and Cyclophosphamide in Women with Locally Advanced HER2-Negative Breast Cancer
Primary objective:To determine the pathologic complete response rate in breast and axillary lymph nodes for patients with HER2-negative locally advanced breast cancer following neoadjuvant therapy
Secondary objectives: Determine 2 year recurrence free-interval.
Determine 2-year overall survival. Determine toxicities of the regimen
| Protocol Number | 041208 |
|---|---|
| Principal Investigator | Antoinette Tan |
| Phase | Phase II |
| Scope | National |
| Applicable Disease Sites | Breast - Female |
| Therapies Involved | Chemotherapy multiple agents systemic |
| Drugs Involved | DOXORUBICIN Eribulin mesylate CYCLOPHOSPHAMIDE PACLITAXEL |
| Participating Institutions | The Cancer Institute of New Jersey |
For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@umdnj.edu.
